중추신경계 림프종 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년 연간 평균 성장률(CAGR) 6.9%로 성장할 전망이며, 16억 7,000만 달러로 성장이 예측됩니다. 예측 기간 동안 성장의 원동력은 개별화 의료에 대한 수요 증가, 조기 진단에 대한 관심 증가, 종양학 연구에 대한 투자 증가, 신규 약물 전달 시스템 도입, 신흥국 시장에서의 헬스케어 인프라 확대, 자가면역질환 유병률 증가, 병용요법 개발, 바이오시밀러 이용 가능성 증가, 암 치료에 대한 원격의료 도입 확대 등입니다. 주요 동향으로는 정밀 의료의 진전, 진단에서의 인공지능 통합, 모니터링을 위한 리퀴드 바이옵시 이용, 나노기술 기반 약물 전달 도입, 이미징 기술의 혁신, 이중특이성 항체 개발, CRISPR(clustered regularly interspaced short palindromic repeats) 등 유전자 편집 기술의 용도, 웨어러블 건강 모니터링 디바이스 도입, 암 치료를 위한 원격의료 플랫폼 확대 등을 들 수 있습니다.
제약업계의 급속한 확대가 중추신경계 림프종 치료 시장의 성장을 견인할 것으로 예측됩니다. 이 업계는 질병의 예방, 치료, 관리를 위한 의약품이나 약제의 연구 개발, 제조, 유통에 중점을 두고 있습니다. 그 성장의 원동력이 되고 있는 것은, 의학 연구의 진보, 인구의 고령화, 세계의 헬스케어 액세스의 확대, 만성 질환의 증가, 세계의 건강 위기, 규제에 의한 지원, 의료비의 증가 등입니다. 제약 분야 확대는 표적 치료의 기술 혁신을 촉진하고 진단 능력을 강화하며 중추신경계 림프종을 포함한 희귀암 연구개발에 대한 투자를 증가시킵니다. 예를 들면, 벨기에에 본부를 둔 제약 업계를 대표하는 업계 단체인 유럽 제약 단체 연합회(EFPIA)는 2024년 6월, 유럽의 의약품 총생산액이 2022년의 3,881억 4,100만 달러(3,633억 유로)에서 2023년에는 4,173억 달러(3,900억 유로)에 이른다고 보고했습니다. 이러한 의약품 산업의 급성장은 중추신경계 림프종 치료의 진보에 기여하고 있습니다.
또한 맞춤형 의료로의 전환이 진행되고 있는 것도 중추신경계 림프종 치료 시장의 성장을 가속할 것으로 예측됩니다. 개별화 의료는 유전적, 환경적, 라이프스타일적인 요인에 따라 개별 환자 맞춤형 치료를 시행하여 치료 결과를 최적화하고 치료를 개선하는 것입니다. 이러한 수요는 유전체학의 진보, 바이오마커에 기반한 진단의 이용 가능성, 데이터 분석 기술의 향상, 보다 목표를 좁힌 효과적인 치료에 대한 요구의 고조로 인해 초래되고 있습니다. 중추신경계 림프종 치료에서는 개별화 의료를 통해 환자 고유의 유전자나 분자 프로파일에 맞춰 치료법을 맞춤형으로 만들 수 있게 돼 정확도가 향상되고 부작용이 감소하며 특히 복잡한 증례나 난치성 증례에서 치료가 성공할 가능성이 높아진다. 예를 들어 2024년 2월 미국 비영리단체인 개별화의료연합(PMC)은 식품의약국(FDA)이 2023년 총 26개의 개별화 치료 중 7개의 새로운 개별화 암 치료를 승인했다고 보고했습니다. 이러한 개별화 의료의 중시의 고조가, 중추 신경계 림프종 치료 시장의 확대에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 중추신경계 림프종 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 중추신경계 림프종 치료 시장 : 성장률 분석
- 세계의 중추신경계 림프종 치료 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 중추신경계 림프종 치료 시장 예측 : 규모 및 성장(2024-2029년 2034년)
- 세계의 중추신경계 림프종 치료 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 중추신경계 림프종 치료 시장 : 치료 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 화학요법
- 방사선 치료
- 표적요법
- 코르티코스테로이드
- 면역요법
- 세계의 중추신경계 림프종 치료 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 정맥내
- 오랄
- 척수내
- 세계의 중추신경계 림프종 치료 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 직접 판매
- 타사 유통업체
- 세계의 중추신경계 림프종 치료 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 외래수술센터(ASC)
- 세계의 중추신경계 림프종 치료 시장 : 화학 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 고용량 메토트렉세이트
- 테모졸로미드
- 리툭시 맵 기반 요법
- 칼무스틴
- 시타라빈
- 세계의 중추신경계 림프종 치료 시장 : 방사선 치료 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 전뇌방사선요법(WBRT)
- 정위 방사선 수술(SRS)
- 근접방사선요법
- 세계의 중추신경계 림프종 치료 시장 : 표적요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 단일클론항체
- 티로신 키나아제 억제제
- B세포 항원 억제제
- PI3K 억제제
- 세계의 중추신경계 림프종 치료 시장 : 코르티코스테로이드 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 덱사메타손
- 프레드니손
- 메틸프레드니솔론
- 세계의 중추신경계 림프종 치료 시장 : 면역요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 체크포인트 억제제
- 키메라 항원 수용체 T 세포(CAR-T) 요법
- 단일클론항체
- 면역조절제
제7장 지역별 및 국가별 분석
- 세계의 중추신경계 림프종 치료 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 중추신경계 림프종 치료 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 중추신경계 림프종 치료 시장 : 경쟁 구도
- 중추신경계 림프종 치료 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
- F Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc 개요, 제품 및 서비스, 전략 및 재무 분석
- AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bristol-Myers Squibb
- Astrazeneca plc
- Novartis AG
- GlaxoSmithKline Plc
- Gilead Sciences
- Amgen Inc
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Baxter International Inc.
- Regeneron Pharmaceuticals
- Biogen Inc.
- UCB Pharma
- Incyte Corporation
- Takeda Pharmaceutical Company Limited
- Seagen Inc.
제32장 세계의 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 중추신경계 림프종 치료 시장(2029년) : 새로운 기회를 제공하는 국가
- 중추신경계 림프종 치료 시장(2029년) : 새로운 기회를 제공하는 부문
- 중추신경계 림프종 치료 시장(2029년) : 성장 전략
제36장 부록
AJY
Central nervous system (CNS) lymphoma treatment involves medical strategies to manage and treat primary or secondary lymphoma affecting the brain, spinal cord, or cerebrospinal fluid (CSF). This treatment typically includes high-dose methotrexate-based chemotherapy, often in combination with other drugs, immunotherapy, radiation therapy, and autologous stem cell transplantation (ASCT). The goal of CNS lymphoma treatment is to eradicate cancer cells while maintaining neurological function and preventing relapse. Treatment plans are customized based on the patient's age, overall health, and disease severity.
The primary treatment methods for CNS lymphoma include chemotherapy, radiation therapy, targeted therapy, corticosteroids, and immunotherapy. Chemotherapy in CNS lymphoma treatment involves using potent anti-cancer drugs to eliminate lymphoma cells within the brain, spinal cord, or other areas of the central nervous system. These drugs can be administered through various routes, including intravenous, oral, and intrathecal delivery. Additionally, distribution channels for these treatments include direct sales and third-party distributors. The key end users of CNS lymphoma treatment include hospitals, clinics, and ambulatory surgical centers.
The central nervous system lymphoma treatment market research report is one of a series of new reports from The Business Research Company that provides central nervous system lymphoma treatment market statistics, including central nervous system lymphoma treatment industry global market size, regional shares, competitors with a central nervous system lymphoma treatment market share, detailed central nervous system lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system lymphoma treatment industry. This central nervous system lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The central nervous system lymphoma treatment market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.28 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to the rising prevalence of central nervous system (CNS) lymphoma, increased adoption of targeted therapies, expansion of cancer awareness programs, higher healthcare expenditure, advancements in immunotherapy, the introduction of high-dose chemotherapy, a surge in clinical trial activities, and improved access to specialized healthcare services.
The central nervous system lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period is expected to be driven by the increasing demand for personalized medicine, a greater focus on early diagnosis, rising investments in oncology research, the introduction of novel drug delivery systems, expanding healthcare infrastructure in emerging markets, a growing prevalence of autoimmune conditions, the development of combination therapies, increased availability of biosimilars, and the growing adoption of telemedicine for cancer care. Major trends include advancements in precision medicine, the integration of artificial intelligence in diagnosis, the use of liquid biopsy for monitoring, the adoption of nanotechnology-based drug delivery, innovations in imaging technologies, the development of bispecific antibodies, the application of gene editing technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), the implementation of wearable health monitoring devices, and the expansion of telehealth platforms for oncology care.
The rapid expansion of the pharmaceutical industry is expected to drive growth in the central nervous system lymphoma treatment market. This industry focuses on researching, developing, manufacturing, and distributing drugs and medications to prevent, treat, and manage diseases. Its growth is fueled by advancements in medical research, an aging population, increased global healthcare access, rising chronic diseases, global health crises, regulatory support, and higher healthcare spending. The pharmaceutical sector's expansion fosters innovation in targeted therapies, enhances diagnostic capabilities, and increases investment in research and development for rare cancers, including central nervous system lymphoma. For example, in June 2024, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry, reported that Europe's total pharmaceutical production reached $417,300 million (€390,000 million) in 2023, up from $388,141 million (€363,300 million) in 2022. This rapid growth in the pharmaceutical industry is contributing to advancements in central nervous system lymphoma treatment.
The increasing shift toward personalized medicine is also expected to propel the growth of the central nervous system lymphoma treatment market. Personalized medicine tailors treatments to individual patients based on genetic, environmental, and lifestyle factors, optimizing outcomes and improving care. This demand is driven by advancements in genomics, the availability of biomarker-based diagnostics, improved data analytics technologies, and a rising need for more targeted and effective therapies. In central nervous system lymphoma treatment, personalized medicine allows therapies to be customized to a patient's unique genetic and molecular profile, improving precision, reducing side effects, and increasing the chances of successful treatment, particularly in complex or refractory cases. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved seven new personalized cancer treatments in 2023, out of a total of 26 personalized treatments, marking a significant rise from the 12 approved in 2022. This growing emphasis on personalized medicine is fueling the expansion of the central nervous system lymphoma treatment market.
Leading companies in the central nervous system lymphoma market are concentrating on innovative therapies, such as chimeric antigen receptor (CAR) T-cell therapy, to enhance treatment effectiveness, provide personalized options, and improve patient outcomes, especially for relapsed or refractory cases. CAR T-cell therapy is an immunotherapy that involves modifying a patient's T-cells to recognize and attack cancer cells more effectively. For example, in June 2024, Kite Pharma, a US-based pharmaceutical company, in collaboration with Dana-Farber Cancer Institute, a US-based cancer treatment center, introduced Yescarta (axicabtagene ciloleucel), a therapy that has shown promising tolerance in patients with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL). Yescarta collects a patient's T-cells, genetically modifies them to target cancer cells, and reintroduces them into the body to destroy lymphoma cells, including those in the central nervous system. This therapy is particularly effective in treating relapsed or difficult-to-treat cases.
Major players in the central nervous system lymphoma treatment market are Pfizer Inc., Johnson & Johnson, F Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Bristol-Myers Squibb, Astrazeneca plc, Novartis AG, GlaxoSmithKline Plc, Gilead Sciences, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals, Biogen Inc., UCB Pharma, Incyte Corporation, Takeda Pharmaceutical Company Limited, Seagen Inc., MorphoSys AG, Nurix Therapeutics, Fresenius SE & Co KGaA, Astellas Pharma, Sandoz Group AG, BeiGene Ltd.
North America was the largest region in the central nervous system lymphoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system lymphoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the central nervous system lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The central nervous system lymphoma treatment market consists of revenues earned by entities by providing services such as diagnostic testing, stem cell transplants, clinical trials and post-treatment care for patients with central nervous system (CNS) lymphoma. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system lymphoma treatment market also includes sales of radiation equipment, diagnostic tools, and supportive care medications used in the treatment of central nervous system (CNS) lymphoma. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Central Nervous System Lymphoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on central nervous system lymphoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for central nervous system lymphoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system lymphoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Chemotherapy; Radiation Therapy; Targeted Therapy; Corticosteroids; Immunotherapy
- 2) By Route Of Administration: Intravenous; Oral; Intrathecal
- 3) By Distribution Channel: Direct Sales; Third-Party Distributors
- 4) By End User: Hospitals; Clinics; Ambulatory Surgical Centers
- Subsegments:
- 1) By Chemotherapy: High-Dose Methotrexate; Temozolomide; Rituximab-Based Regimens; Carmustine; Cytarabine
- 2) By Radiation Therapy: Whole Brain Radiation Therapy (WBRT); Stereotactic Radiosurgery (SRS); Brachytherapy
- 3) By Targeted Therapy: Monoclonal Antibodies; Tyrosine Kinase Inhibitors; B-Cell Antigen Inhibitors; PI3K Inhibitors
- 4) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone
- 5) By Immunotherapy: Checkpoint Inhibitors; Chimeric Antigen Receptor T-Cell (CAR-T) Therapy; Monoclonal Antibodies; Immune Modulators
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F Hoffmann-La Roche AG; Merck & Co. Inc; AbbVie Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Central Nervous System Lymphoma Treatment Market Characteristics
3. Central Nervous System Lymphoma Treatment Market Trends And Strategies
4. Central Nervous System Lymphoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Central Nervous System Lymphoma Treatment Growth Analysis And Strategic Analysis Framework
- 5.1. Global Central Nervous System Lymphoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Central Nervous System Lymphoma Treatment Market Growth Rate Analysis
- 5.4. Global Central Nervous System Lymphoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Central Nervous System Lymphoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Central Nervous System Lymphoma Treatment Total Addressable Market (TAM)
6. Central Nervous System Lymphoma Treatment Market Segmentation
- 6.1. Global Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Corticosteroids
- Immunotherapy
- 6.2. Global Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous
- Oral
- Intrathecal
- 6.3. Global Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Direct Sales
- Third-Party Distributors
- 6.4. Global Central Nervous System Lymphoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- 6.5. Global Central Nervous System Lymphoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- High-Dose Methotrexate
- Temozolomide
- Rituximab-Based Regimens
- Carmustine
- Cytarabine
- 6.6. Global Central Nervous System Lymphoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Whole Brain Radiation Therapy (WBRT)
- Stereotactic Radiosurgery (SRS)
- Brachytherapy
- 6.7. Global Central Nervous System Lymphoma Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- B-Cell Antigen Inhibitors
- PI3K Inhibitors
- 6.8. Global Central Nervous System Lymphoma Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dexamethasone
- Prednisone
- Methylprednisolone
- 6.9. Global Central Nervous System Lymphoma Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Checkpoint Inhibitors
- Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
- Monoclonal Antibodies
- Immune Modulators
7. Central Nervous System Lymphoma Treatment Market Regional And Country Analysis
- 7.1. Global Central Nervous System Lymphoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Central Nervous System Lymphoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Central Nervous System Lymphoma Treatment Market
- 8.1. Asia-Pacific Central Nervous System Lymphoma Treatment Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Central Nervous System Lymphoma Treatment Market
- 9.1. China Central Nervous System Lymphoma Treatment Market Overview
- 9.2. China Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Central Nervous System Lymphoma Treatment Market
- 10.1. India Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Central Nervous System Lymphoma Treatment Market
- 11.1. Japan Central Nervous System Lymphoma Treatment Market Overview
- 11.2. Japan Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Central Nervous System Lymphoma Treatment Market
- 12.1. Australia Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Central Nervous System Lymphoma Treatment Market
- 13.1. Indonesia Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Central Nervous System Lymphoma Treatment Market
- 14.1. South Korea Central Nervous System Lymphoma Treatment Market Overview
- 14.2. South Korea Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Central Nervous System Lymphoma Treatment Market
- 15.1. Western Europe Central Nervous System Lymphoma Treatment Market Overview
- 15.2. Western Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Central Nervous System Lymphoma Treatment Market
- 16.1. UK Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Central Nervous System Lymphoma Treatment Market
- 17.1. Germany Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Central Nervous System Lymphoma Treatment Market
- 18.1. France Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Central Nervous System Lymphoma Treatment Market
- 19.1. Italy Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Central Nervous System Lymphoma Treatment Market
- 20.1. Spain Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Central Nervous System Lymphoma Treatment Market
- 21.1. Eastern Europe Central Nervous System Lymphoma Treatment Market Overview
- 21.2. Eastern Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Central Nervous System Lymphoma Treatment Market
- 22.1. Russia Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Central Nervous System Lymphoma Treatment Market
- 23.1. North America Central Nervous System Lymphoma Treatment Market Overview
- 23.2. North America Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Central Nervous System Lymphoma Treatment Market
- 24.1. USA Central Nervous System Lymphoma Treatment Market Overview
- 24.2. USA Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Central Nervous System Lymphoma Treatment Market
- 25.1. Canada Central Nervous System Lymphoma Treatment Market Overview
- 25.2. Canada Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Central Nervous System Lymphoma Treatment Market
- 26.1. South America Central Nervous System Lymphoma Treatment Market Overview
- 26.2. South America Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Central Nervous System Lymphoma Treatment Market
- 27.1. Brazil Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Central Nervous System Lymphoma Treatment Market
- 28.1. Middle East Central Nervous System Lymphoma Treatment Market Overview
- 28.2. Middle East Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Central Nervous System Lymphoma Treatment Market
- 29.1. Africa Central Nervous System Lymphoma Treatment Market Overview
- 29.2. Africa Central Nervous System Lymphoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Central Nervous System Lymphoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Central Nervous System Lymphoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Central Nervous System Lymphoma Treatment Market Competitive Landscape And Company Profiles
- 30.1. Central Nervous System Lymphoma Treatment Market Competitive Landscape
- 30.2. Central Nervous System Lymphoma Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Central Nervous System Lymphoma Treatment Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb
- 31.2. Astrazeneca plc
- 31.3. Novartis AG
- 31.4. GlaxoSmithKline Plc
- 31.5. Gilead Sciences
- 31.6. Amgen Inc
- 31.7. Viatris Inc.
- 31.8. Teva Pharmaceutical Industries Ltd.
- 31.9. Baxter International Inc.
- 31.10. Regeneron Pharmaceuticals
- 31.11. Biogen Inc.
- 31.12. UCB Pharma
- 31.13. Incyte Corporation
- 31.14. Takeda Pharmaceutical Company Limited
- 31.15. Seagen Inc.
32. Global Central Nervous System Lymphoma Treatment Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Central Nervous System Lymphoma Treatment Market
34. Recent Developments In The Central Nervous System Lymphoma Treatment Market
35. Central Nervous System Lymphoma Treatment Market High Potential Countries, Segments and Strategies
- 35.1 Central Nervous System Lymphoma Treatment Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Central Nervous System Lymphoma Treatment Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Central Nervous System Lymphoma Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
